KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Cash & Equivalents (2018 - 2025)

Vir Biotechnology's Cash & Equivalents history spans 8 years, with the latest figure at $232.2 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 159.76% to $232.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $232.2 million, a 159.76% increase, with the full-year FY2025 number at $232.2 million, up 159.76% from a year prior.
  • Cash & Equivalents hit $232.2 million in Q4 2025 for Vir Biotechnology, up from $2.2 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for VIR hit a ceiling of $1.5 billion in Q2 2022 and a floor of $2.2 million in Q3 2025.
  • Historically, Cash & Equivalents has averaged $327.1 million across 5 years, with a median of $200.3 million in 2024.
  • Biggest five-year swings in Cash & Equivalents: surged 21390.33% in 2022 and later tumbled 98.68% in 2025.
  • Tracing VIR's Cash & Equivalents over 5 years: stood at $347.8 million in 2021, then tumbled by 96.35% to $12.7 million in 2022, then increased by 4.63% to $13.3 million in 2023, then skyrocketed by 573.69% to $89.4 million in 2024, then skyrocketed by 159.76% to $232.2 million in 2025.
  • Business Quant data shows Cash & Equivalents for VIR at $232.2 million in Q4 2025, $2.2 million in Q3 2025, and $88.2 million in Q2 2025.